Tom Price Confirmed as HHS Director

The orthopedic surgeon is confirmed to lead the US Department of Health and Human Services.

Written byJoshua A. Krisch
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

WIKIMEDIA, GAGE SKIDMORERepresentative Tom Price (R-GA), the orthopedic surgeon selected by President Donald Trump to head the US Department of Health and Human Services (HHS) was confirmed today (February 10) after a series of grueling Senate hearings. Price was confirmed in the wee hours of the morning, by a Senate vote of 52 to 47. He will be the first physician to direct HHS—which oversees the National Institutes of Health (NIH), the Food and Drug Administration (FDA), and the Centers for Disease Control and Prevention (CDC)—since Louis Sullivan stepped down from the post in 1993.

During the hearings, Price came under fire for alleged conflicts of interest in some of his private investments. He was also a controversial pick due to his long-held opposition to the Affordable Care Act and plans for overhauling Medicare and Medicaid. “Buying and selling healthcare stocks as a member of Congress while you’re voting and helping those companies, that’s bad enough,” Senator Sherrod Brown (D-OH) told The New York Times. “But what he wants to do to maybe the greatest program in American history, Medicare, is much, much worse.”

But Republicans are hailing the confirmation as a victory. Price, who will indirectly control the NIH, FDA, and CDC, is “one of the most capable, well-prepared individuals that President Trump could have chosen,” Senator Michael Enzi ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies